Illustration of a lady watering plants.

Huma leads digital-first patient
care with 'hospital at home'

Our 'hospital at home' technology collects real-world patient data remotely. It connects patients and clinical teams, enables greater access to care from any location and improves efficiency for clinicians.

Improving clinical outcomes

27m+

Huma's digital-first health platforms are having a global impact across a network of 27m patients

3000+

3000+ hospitals and clinics supported across Huma platform to secure the most sustainable impact for patients

90-90%

adherence and retention rates across our care and research deployments are the result of high engagement rates

×2

Our platform can almost double clinical capacity and reduce readmission rates by >30%1

Talk to us

Patient App

How do we support patients?

Through our app, patients access a care plan configured for their needs from a library of modules and features. The app enables real-time data capture for clinicians and delivers targeted educational content to patients, empowering them to better track and manage their health.

Timeline of tasks

Patients are given a timeline outlining the tasks they need to complete and they receive timely reminders.

Questionnaires

The app provides validated clinical questionnaires, for example the Oxford Knee Score, EQ-5D, Global Health Score and Promis CAT.

Device integration

We connect to a number of medical devices to aid data collection.

Vital signs

Patients can use their phones and integrated devices to capture and monitor health vitals safely and remotely.

Educational content

We support patients with educational content about their symptoms, care and treatment.

Telemedicine

Patients can receive additional support from their clinical team through secure video and audio consultations.

  • Timeline of tasks
  • Vital signs
  • Questionnaires
  • Educational content
  • Device integration
  • Telemedicine

Patients are given a timeline outlining the tasks they need to complete and they receive timely reminders.

Patients can use their phones and integrated devices to capture and monitor health vitals safely and remotely.

The app provides validated clinical questionnaires, for example the Oxford Knee Score, EQ-5D, Global Health Score and Promis CAT.

We support patients with educational content about their symptoms, care and treatment.

We connect to a number of medical devices to aid data collection.

Patients can receive additional support from their clinical team through secure video and audio consultations.

WEB-BASED PORTAL

How do we support
healthcare professionals?

We aid clinical 'decision making' by providing care teams with real-time visibility of patient data through a web-based portal. The portal features automated flagging systems, trend visualisation and telemedicine for direct communication.

  • Integration to health systems and data exporting

    Clinicians can export data from the web-based portal in multiple formats. The care team portal can also be integrated with electronic health systems or data registries to enable automatic export based on set timeframes.

  • Telemedicine and appointments

    Clinicians can quickly and securely speak to patients through video and audio calls and schedule in-person consultations to ensure they are on track with their care plan and to check any irregularities flagged in their health records.

  • Cohort management and prioritisation

    Clinicians can manage multiple patients within a web-based portal. The technology automatically flags patients that might need prioritising, based on data generated through the app.

  • Monitoring of individual patients

    The portal can display information about individual patients and visualise data trends. Clinicians can add notes and collaborate with colleagues to ensure the patient receives the optimal care they need.

  • Integration to health systems and data exporting

    Clinicians can export data from the web-based portal in multiple formats. The care team portal can also be integrated with electronic health systems or data registries to enable automatic export based on set timeframes.

  • Telemedicine and appointments

    Clinicians can quickly and securely speak to patients through video and audio calls and schedule in-person consultations to ensure they are on track with their care plan and to check any irregularities flagged in their health records.

  • Cohort management and prioritisation

    Clinicians can manage multiple patients within a web-based portal. The technology automatically flags patients that might need prioritising, based on data generated through the app.

  • Monitoring of individual patients

    The portal can display information about individual patients and visualise data trends. Clinicians can add notes and collaborate with colleagues to ensure the patient receives the optimal care they need.

Explore
'Hospital at Home' further

This field is required

Thumbs up for inqury.
One of our team members will be in touch with you shortly.
There was an error submitting your form. Please refresh and try again.

Our experience in
delivering better research

  • phase iv trial
  • atrial fibrillation
  • covid-19
  • diabetes

Supporting AstraZeneca with
an international Phase IV study

AstraZeneca selected our DCT platform to support one of the world’s largest decentralized clinical trials. Designed to use remote recruitment, ID verification, and safety data collection through our secure platform, the first patient was recruited less than three months after the project was signed. In order to ensure access for all populations, participants have multiple means to engage and are able to submit data on either an app, web portal or through a call centre.

Watch video

Powering a DCT in atrial fibrillation
with Bayer and Stanford Medicine

Huma, Bayer, Stanford Medicine and the Stanford Center for Digital Health together demonstrated the feasibility, for the first time, of a scalable, fully decentralized cardiovascular intervention trial requiring remote physiologic measurements among participants with atrial fibrillation. The trial had a robust recruitment strategy and strong engagement. Participants successfully transmitted physiologic BP and ECG measurements, tracked OAC adherence, completed regular surveys and televisits using Huma’s DCT platform. The findings provide a strong foundation to inform the design and conduct of future decentralized protocols for cardiovascular trials.

Watch video

Pioneering a decentralized clinical study
with the University of Cambridge

Huma partnered with the University of Cambridge (Medical Research Council Epidemiology Unit) to understand the progression of COVID-19 infection and build predictive models for pre-symptomatic infection. The study uses Huma’s digital platform to remotely collect data from nearly 2,500 participants from the Fenland cohort. This builds on 15 years worth of retrospective data to generate new insights and a joint analytics dataset for digital biomarker discovery.

Watch video

Interventional Trial For High-Risk
Type 2 Diabetes Patients

The study is a collaboration between Huma, Astra Zeneca and Imperial Health Partners. With the initial promising results from the interventional trial that included 600 participants, the aim is to scale the programme nationally, to create a real-world dataset to support high-quality research and transform care pathways for patients with type 2 diabetes, reducing complications and improving outcomes.

Watch video

Find out more

Talk to us

Regulatory, safety and compliance

Regulatory logo.

ISO certifications

  • ISO 13485: 2016 certified (Medical Devices: Quality Management Systems)
  • ISO 27001: 2013 certified (Information Security)

Medical device registrations

  • US FDA Class I exempt and enforcement discretion
  • CE marked class I Medical Device
  • Registered with the MHRA as a Medical Device

Data protection / infosec

  • GDPR compliant
  • NHS Registration on Data Security and Protection Toolkit
  • CyberEssentials / CyberEssentials Plus

US FDA 21 CFR compliences

  • Part 11
  • Part 5D
  • Part 820 ff

Talk to us

This field is required

This field is required

This field is required

This field is required

Huma is committed to respecting your privacy, and we’ll only use your personal details to provide information you have selected you’re interested in. Review our Privacy Policy for further information.

We’d love to send you our monthly newsletter about our latest work, research and events by email. We’ll always treat your personal details with the utmost care and will never sell them to other companies for marketing purposes.

This field is required

Country/Region
Afghanistan
Åland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua and Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bosnia and Herzegovina
Botswana
Bouvet Island
Brazil
British Indian Ocean Territory
Brunei Darussalam
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo
Congo, The Democratic Republic of the
Cook Islands
Costa Rica
Cote D"Ivoire
Croatia
Cuba
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands (Malvinas)
Faroe Islands
Fiji
Finland
France
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Heard Island and Mcdonald Islands
Holy See (Vatican City State)
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran, Islamic Republic Of
Iraq
Ireland
Isle of Man
Israel
Italy
Jamaica
Japan
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Korea, Democratic People"S Republic of
Korea, Republic of
Kuwait
Kyrgyzstan
Lao People"S Democratic Republic
Latvia
Lebanon
Lesotho
Liberia
Libyan Arab Jamahiriya
Liechtenstein
Lithuania
Luxembourg
Macao
Macedonia, The Former Yugoslav Republic of
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia, Federated States of
Moldova, Republic of
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
Netherlands Antilles
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territory, Occupied
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Reunion
Romania
Russian Federation
RWANDA
Saint Helena
Saint Kitts and Nevis
Saint Lucia
Saint Pierre and Miquelon
Saint Vincent and the Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia and the South Sandwich Islands
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Swaziland
Sweden
Switzerland
Syrian Arab Republic
Taiwan, Province of China
Tajikistan
Tanzania, United Republic of
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States
United States Minor Outlying Islands
Uruguay
Uzbekistan
Vanuatu
Venezuela
Viet Nam
Virgin Islands, British
Virgin Islands, U.S.
Wallis and Futuna
Western Sahara
Yemen
Zambia
Zimbabwe

This field is required

I'm interested in
Companion app for Pharmaceutical companies
Companion app for MedTech companies
Decentralised Clinical Trials (DCT)
Hospital @ Home
Software as a Medical Device (SaMD)
Partnering with Huma
Other

This field is required

Huma is committed to respecting your privacy, and we’ll only use your personal details to provide information you have selected you’re interested in. Review our Privacy Policy for further information.

We’d love to send you our monthly newsletter about our latest work, research and events by email. We’ll always treat your personal details with the utmost care and will never sell them to other companies for marketing purposes.

You’re in control. You can, of course, withdraw your consent at any time. Review our Privacy Policy for further information.

Success message with thumbs up for filling out the form.
One of our team members will be in touch with you shortly.
There was an error submitting your form. Please refresh and try again.

Sources

1. nhsx.nhs.uk/covid-19-response/technology-nhs/huma-medopad-evaluation-remote-digital-care-platform/
The full report is available on request. Patient feedback based on sample size of 30 responses

3. Data from 2021 single-arm, six-month study. Paper in submission

2. Publication in production

4. Data from 2021 pilot study. Full evaluation of the service is in preparation

Cookie settings

Read more